Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects

Non-alcoholic Fatty Liver Disease Clinical Trial

— LIGHT-ON  

Official title:

Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02147925
• Other study ID #: IIS201404
• Status: Completed
• Phase: Phase 4
• Start date: August 2014
• Est. completion date: April 2017

Study information

• Verified date: October 2017
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to explore the effectiveness of liraglutide combined with metformin in non-alcoholic fatty-liver disease patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and insulin glargine in combination with metformin.

Description:

This is a 26-week, randomized, open-label, active controlled, parallel group, multi-centre trial.To compare the change of intrahepatic lipids (IHL) as measured by magnetic resonance spectroscopy(MRS) or MRI estimated proton density fat fraction (MRI-PDFF) as measured by MRI IDEAL IQ (Iterative Decomposition of water andfat with Echo Asymmetryand Least-squares estimation) in type 2 diabetic patients with non-alcoholic fatty-liver disease after a 26-week treatment of liraglutide, sitagliptin or insulin glargine per day combined with metformin.The primary endpoint will be defined by intrahepatic lipids (IHL) as measured by magnetic resonance spectroscopy (MRS) or MRI-PDFF as measured by MRI IDEAL IQ.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: April 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

• Recorded Type 2 diabetes diagnosed at least 3 months before the study; At least 3 months treatment on a stable dose(?1500mg/d)of metformin before the study

• 6.5%<HbA1c =10%

• Clinically diagnosed simple liver steatosis

• 30-75 years old

• Female subjects should be postmenopausal, surgically sterile, or using contraceptives for 3 months before screening and continuing throughout the study;

• BMI 20~35 kg/m2 and with a history of stable body weight (=10%variation for =3 months)

• intrahepatic lipids (IHL) >10%

Exclusion Criteria:

• Type 1 diabetes

• Treatment within the last 3 months with Thiazolidinediones(TZDs), orlistat, insulin, any history of incretin based therapy or any other drugs associated with hepatic steatosis (including but not limited to glucocorticoids, tamoxifen, amiodarone or methotrexate)

• History or current episode of pancreatitis or other disease of the pancrea; Impaired liver function, defined as plasma alanine transaminase(ALT) >2.5 times of upper normal limit

• Moderate and severe renal insufficiency defined as MDRD formula glomerular filtration rate<60ml/min/1.73m2

• Weekly alcohol intake>14 units for women or >21 units for men

• Any history of liver disease including metabolic or auto-immune liver diseases or viral hepatitis

• History or family history of medullary thyroid cancer(MTC), or multiple endocrine neoplasia type 2(MEN-2)

• Congestive heart failure(NYHA III~IV)

• Severe gastric-intestinal diseases

• Pregnancy and/or intention of becoming pregnant

• Known proliferative retinopathy or maculopathy requiring acute treatment as judged by the Investigator; Use of non-herbal Chinese medicine or other non-herbal local medicine with unknown/unspecified content. Herbal traditional Chinese medicine or other local herbal medicines may, at the Investigator's discretion, be continued throughout the trial at an unchanged dose

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-alcoholic Fatty Liver Disease

Intervention

Drug:
• Liraglutide combined with metformin
Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
• Insulin glargine combined with metformin
The initial dose will be 0.2 unit/kg/d
• Sitagliptin combined with metformin
The dose throughout the study will be 100mg per day.

Locations

Country	Name	City	State
China	The Third Affiliated Hospital of Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intrahepatic lipids (IHL)	To compare the change of intrahepatic lipids (IHL) in type 2 diabetic patients with non-alcoholic fatty-liver disease after a 26-week treatment of liraglutide, sitagliptin or insulin glargine per day combined with metformin.	26-week
Secondary	Change of abdominal subcutaneous adipose tissue(SAT)	To compare the change of SAT in type 2 diabetic patients	26 weeks
Secondary	Change of visceral adipose tissue(VAT)	To compare the change of VAT in type 2 diabetic patients	26 weeks
Secondary	Change in hemoglobin A1c(HbA1c)	To compare the change of HbA1c in type 2 diabetic patients	26 weeks